BioNTech veröffentlicht Ergebnisse für das dritte Quartal 2025 sowie Informationen zur Geschäftsentwicklung
View original at globenewswire.com“Nettoverlust in Höhe von 28,7 Millionen Euro (table: "Nettogewinn / (-verlust) (28,7)" for Drittes Quartal 2025, with "In Mio. €" as the unit)”
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Pumitamig showed encouraging anti-tumor activity, positive PFS trend, controlled safety profile, and low discontinuation rate in ES-SCLC Phase 2 trial
80% confidenceBioNTech expects no positive net income for FY 2025
80% confidenceROSETTA Breast-01 Phase 3 trial for TNBC will start by end of 2025
80% confidenceTrastuzumab Pamirtecan BLA filing planned for 2026 pending FDA feedback
80% confidenceAutogene Cevumeran showed strong durable immune responses up to 1.5 years post-treatment with broad immune response correlated with extended PFS
80% confidenceBNT111 demonstrated deep durable antitumor responses with statistically significant improvement in ORR vs historical control
80% confidence2025 CapEx expected to be €200-250M, reduced from previous guidance of €250-350M
80% confidence2025 revenue guidance is €2,600-2,800M
80% confidence2025 SG&A costs expected to be €550-650M, reduced from previous guidance of €650-750M
80% confidence2025 R&D costs expected to be €2,000-2,200M, reduced from previous guidance of €2,600-2,800M
80% confidence
Data points we hold from this source
| BioNTech SE · outstanding shares | 240455450 shares |
| BioNTech SE · r and d costs | 564.8 million_EUR |
| BioNTech SE · sg and a costs | 148.5 million_EUR |